David Prince
US Equity/Options Fund Manager, Mentor at T3 Live
Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com x.comÂ
ImmunityBio's market cap still looks absurd despite falling sharply from its bubble-era level. Its merger of several companies at the 2021 peak has kept the stock off the buy list. x.comÂ
Biotech is drawing some of the largest long-term buying ever into the SPDR S&P Biotech ETF as it pushes toward its 2021 all-time high. Heavy buy volume, including another historic dollar-volume spike last week, matters more than short-term uncertainty, and the selling has been inefficient. If price loses $154.20 again, the bear case comes back into play. x.comÂ
Zenas BioPharma's clinical data do not meet the best-in-class or first-in-class standard after closer review. It no longer fits the investment criteria despite the earlier view of its late-stage potential and cheap valuation. x.com x.comÂ
Genomics stocks appear to be benefiting from AI, with the ARK Genomic Revolution ETF clearly outpacing broader biotech. x.comÂ
Biotech looks like a sector that wants to trend higher. Biotech M&A drove a heavy-volume weekly move to the top of a multi-month range; it just needs some help from the macro environment. x.comÂ
US healthcare and biotech stocks are coming under distribution as the attack on healthcare returns. Per Dr Alex Kenton, the No Surprises Act has knocked millions of people off insurance rolls, hurting hospitals, and a new Justice Department investigation targets Cigna, UnitedHealth and CVS over allegedly using Claritev to fix prices. x.comÂ
Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.comÂ
Biotech is back. A quoted report says lab monkey prices in China have surged to about $26,000 each as the biotech boom overwhelms supply. x.comÂ
Small caps have the best chart of the three major US indexes, and money is flowing into the financials and biotech names the Russell 2000 is full of. The position was started on the post-FOMC flush and will be managed against the 9-day EMA, with the risk of exiting if Fed chair Warsh's press conference goes the wrong way. x.comÂ